PHC To Exclusively Distribute MaxCyte Cell Engineering Platform In Japan
KUALA LUMPUR, July 1 (Bernama) -- The Biomedical Division of PHC Corporation (PHCbi), a subsidiary of PHC Holdings Corporation (PHCHD), has signed an exclusive distribution agreement with United States-based MaxCyte Inc to bring the company’s advanced ExPERT cell engineering platform to the Japanese market.
The partnership expands PHCbi’s presence in next-generation cell and gene therapy (CGT) technologies and strengthens its commitment to supporting innovation in regenerative medicine and bioproduction.
PHC Corporation Director and PHCbi General Manager, Chikara Takauo said this partnership reinforces its commitment to advancing therapeutic modalities by offering solutions that address quality, cost, and delivery (QCD) challenges in CGT manufacturing.
“We are pleased to add MaxCyte’s ExPERT instruments to our cell culture technology portfolio,” he said in a statement.
As part of the deal, PHCbi will provide sales and service support for MaxCyte’s full suite of electroporation systems, including the ExPERT ATx, STx, GTx, and VLx platforms, along with related consumables such as processing assemblies and electroporation buffers.
The ExPERT line is globally recognised for its high transfection efficiency, scalability, and non-viral delivery method — features that have made it a key enabling technology in more than 70 clinical programmes as of the first quarter of 2025.
In a parallel agreement, SciMed (Asia) Pte Ltd, another PHCHD subsidiary, has also signed an exclusive distribution deal with MaxCyte, launching the ExPERT platform in Singapore in June.
PHCbi’s expanded CGT portfolio also includes recently introduced innovations such as the LiCellMo live-cell metabolic analyser and the upcoming LiCellGrow cell expansion system, both designed to optimise the efficiency and precision of cell culture and monitoring.
Together with MaxCyte’s technology, these offerings aim to provide comprehensive tools for researchers and manufacturers in the fields of immunotherapy, regenerative medicine, and advanced bioproduction.
PHCbi will showcase the ExPERT Platform at the Seventh Regenerative Medicine EXPO Tokyo 2025 in Japan, which will be held at Japan’s Tokyo Big Sight from July 9 to 11.
-- BERNAMA